Article
Covid-19 roundup: Eli Lilly declares success on JAK blocker in NIH trial; UK gives small biotech a
Rating:
0.0
Views:
112
Likes:
1
Library:
1
The NIH-led study that gave the world the first positive, randomized remdesivir result has come back with a second one, showing that, when combined with remdesivir, an Eli Lilly molecule can slightly improve on time to recovery over remdesivir alone. The ACTT-2 trial, a follow-up that began after the remdesivir
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value